Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider David Y. Liu sold 7,000 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $16.97, for a total transaction of $118,790.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) traded up $1.13 on Friday, hitting $17.40. 97,752 shares of the stock traded hands, compared to its average volume of 84,310. Protagonist Therapeutics, Inc. has a 52 week low of $8.00 and a 52 week high of $26.36.
Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Monday, November 6th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.40. The company had revenue of $8.78 million for the quarter. sell-side analysts expect that Protagonist Therapeutics, Inc. will post -3.66 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: Protagonist Therapeutics, Inc. (PTGX) Insider Sells $118,790.00 in Stock” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2017/11/18/insider-selling-protagonist-therapeutics-inc-ptgx-insider-sells-118790-00-in-stock.html.
Several hedge funds and other institutional investors have recently modified their holdings of PTGX. Rhumbline Advisers bought a new stake in shares of Protagonist Therapeutics during the second quarter valued at about $114,000. Wells Fargo & Company MN raised its stake in shares of Protagonist Therapeutics by 60.8% during the third quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock valued at $169,000 after purchasing an additional 3,617 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of Protagonist Therapeutics by 71.4% during the second quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after purchasing an additional 6,757 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Protagonist Therapeutics by 8.5% during the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Northern Capital Management LLC bought a new stake in shares of Protagonist Therapeutics during the second quarter valued at about $188,000. Institutional investors and hedge funds own 39.73% of the company’s stock.
Several brokerages have recently issued reports on PTGX. Zacks Investment Research raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Friday, August 18th. BMO Capital Markets boosted their price target on shares of Protagonist Therapeutics from $40.00 to $43.00 and gave the company an “outperform” rating in a report on Tuesday, November 7th. ValuEngine downgraded shares of Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 11th. Finally, BTIG Research began coverage on shares of Protagonist Therapeutics in a report on Friday, July 21st. They set a “buy” rating and a $36.00 price target for the company.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.